PREPARING FOR
THE NEW POSSIBLE
November 14 – 15, 2018 • Harvard Medical School, Boston, MA
Schedule
Part I
The Infrastructure for Innovation
“We need to make the transition to a predict, prevent and protect health system.”
Senior Vice President, Global Value, Access and Policy, Amgen
*** Speakers will be added to the schedule on a rolling basis as they are confirmed. ***
Joseph B. Martin Conference Center at Harvard Medical School
77 Avenue Louis Pasteur, Boston, MA 02115
SPEAKER | Edward Abrahams, Ph.D., President, Personalized Medicine Coalition
SPEAKER | Elizabeth Nabel, M.D., President, Brigham and Women’s Hospital
Government executives have an enormous influence over the direction of health systems and can therefore play a role in developing personalized medicine — but they need to know what works and what doesn’t if their respective efforts to promote personalized medicine are going to succeed. With that in mind, government representatives from around the globe will discuss the competitive advantages various countries have in personalized medicine and explore the common challenges and notable achievements of government initiatives to advance the field during this panel discussion.
MODERATOR | Antonio L. Andreu, M.D., Ph.D., Scientific Director, EATRIS European Infrastructure for Translational Medicine
Ora Dar, Ph.D., Senior Expert, Medical Sciences, consultant to the Israel Innovation Authority
Tom Fowler, Ph.D., Deputy Chief Scientist, Genomics England
Marc LePage, President, CEO, Genome Canada
Liisa-Maria Voipio-Pulkki, M.D., Ph.D., Director General, Chief Medical Officer, Ministry of Social Affairs and Health, Finland
Light refreshments provided.
MODERATOR | Susan McClure, Founder, Publisher, Genome magazine; Board Member, Personalized Medicine Coalition
Emily Kramer-Golinkoff, Co-Founder, Emily’s Entourage, cystic fibrosis patient
Bryce Olson, Global Marketing Director, Health and Life Sciences Group, Intel Corporation; stage IV prostate cancer patient
Artificial intelligence may help inform personalized medicine in the future by perceiving which genes, proteins and other biological characteristics contribute to human disease. During this session, a diverse panel will discuss how artificial intelligence may accelerate drug development, improve clinical decision support and drive patient outcomes — and what that might mean for the future of health care.
MODERATOR | Colin Hill, Chairman, CEO, Co-Founder, GNS Healthcare
Tom Miller, Managing Partner, GreyBird Ventures LLC
Gregg Talbert, Ph.D., Global Head of Digital and Personalized Health Care Partnering, Roche
Darrell M. West, Ph.D., Vice President of Governance Studies and Director of Center for Technology Innovation, Douglas Dillon Chair in Governance Studies, The Brookings Institution
SPEAKER | David King, J.D., Chairman, CEO, LabCorp
The U.S. Food and Drug Administration and the U.S. Centers for Medicare and Medicaid Services have been working for over a decade to develop regulatory and reimbursement pathways that promote the development of innovative diagnostic tests. Many observers, however, believe the current regulatory and reimbursement landscape still limits the field. This panel of business leaders will discuss the extent to which the existing frameworks and proposed policies may help or hinder personalized medicine.
MODERATOR | Joseph V. Ferrara, CEO, Boston Healthcare Associates
Michael Doherty, Senior Vice President, Head of Product Development, Head of Research & Development, Foundation Medicine
Julie Khani, President, American Clinical Laboratory Association
Kimberly Popovits, Chairman of the Board, CEO, President, Genomic Health
Mark P. Stevenson, Executive Vice President, Chief Operating Officer, Thermo Fisher Scientific
Light refreshments provided.
Sponsored By
The U.S. Food and Drug Administration (FDA) remains firmly committed to regulatory strategies designed to advance personalized medicine. During this wide-ranging fireside chat, two senior leaders from government and industry will discuss the agency’s latest actions impacting the oversight of personalized medicine products and services. The discussion will cover topics including but not limited to next-generation sequencing, diagnostic test regulation, digital health, and real-world evidence.
MODERATOR | Cynthia A. Bens, Senior Vice President, Public Policy, Personalized Medicine Coalition
Jesse Berlin, Sc.D., Vice President and Global Head of Epidemiology, Johnson and Johnson
Lauren Silvis, J.D., Chief of Staff, Immediate Office of the Commissioner, FDA
Advancing a medical paradigm that focuses on the unique characteristics of each patient will require, by definition, that patients from diverse backgrounds participate in the medical studies that advance our understanding of disease. Also critical is the need to ensure that those patients have access to personalized care informed by those studies. During this session, four panelists will discuss the effort to ensure that all patient populations benefit equally from personalized medicine.
MODERATOR | Donna R. Cryer, J.D., President, CEO, Global Liver Institute
Vence L. Bonham, Jr., J.D., Senior Advisor, Director on Genomics and Health Disparities, U.S. National Human Genome Research Institute
Alex J. Carlisle, Ph.D., Chairman, CEO, National Alliance Against Disparities in Patient Health
Adolph P. Falcón, Executive Vice President, National Alliance for Hispanic Health
Edward Tepporn, Executive Vice President, Asian & Pacific Islander American Health Forum
SPEAKER | Amy Abernethy, M.D., Ph.D., Chief Medical Officer, Chief Scientific Officer, Senior Vice President, Oncology, Flatiron Health
Avenue of the Arts
465 Huntington Avenue
Boston, MA 02115
Sponsored by
Welcome Reception
At the Boston Museum of Fine Arts
November 14, 2018 – 6:15 p.m.
465 Huntington Ave., Boston, MA 02115
Sponsored by
Part II
The Business of Personalization
“The successful implementation of [personalized medicine] will depend on the embrace of [its] principles in the business community.”
Paul C. Cabot Professor of Genetics, Harvard Medical School
*** Speakers will be added to the schedule on a rolling basis as they are confirmed. ***
Joseph B. Martin Conference Center at Harvard Medical School
77 Avenue Louis Pasteur, Boston, MA 02115
SPEAKER | Stephen L. Eck, M.D., Ph.D., Chief Medical Officer, Immatics U.S. Inc; Board Chair, Personalized Medicine Coalition
MODERATOR | Meg Tirrell, Reporter, CNBC
Daniel O’Day, CEO, Roche Pharmaceuticals
The pharmaceutical industry is deeply invested in commercializing personalized therapies that must recoup fixed development costs from smaller patient populations covered by health insurance companies that are increasingly concerned about rising health care costs. In that context, this diverse panel will explore the viability of the business model for developing and paying for personalized medicines, tackling issues related to costs, prices, and access.
MODERATOR | Meg Tirrell, Reporter, CNBC
Peter Juhn, M.D., M.P.H., Global Head of Value-Based Partnerships, Amgen
Nick Leschly, CEO, Bluebird Bio
Michael Sherman, M.D., Chief Medical Officer, Senior Vice President, Harvard Pilgrim Health Care
Sean Tunis, M.D., Founder, CEO, Center for Medical Technology Policy
Light refreshments provided.
Sponsored By
Recognizing that traditional randomized controlled clinical trials can only study the safety and efficacy of a single therapy in one large population of patients, researchers in personalized medicine increasingly hope that “adaptive platform trials,” which employ advanced statistical techniques to simultaneously test the effectiveness of several personalized treatments in multiple sub-populations of patients, may be the key to new drug approvals in the future. Adaptive platform trials may make drug development more efficient by revealing which of several drug candidates are most promising for which patients, but maximizing the potential of these trials requires unprecedented collaboration among the institutions conducting and sponsoring research on various personalized treatments — and no obvious business models have emerged.
During this interactive case study discussion, professors from Harvard Business School will help us examine how researchers at the Dana-Farber Cancer Institute considered and addressed myriad challenges in their effort to design and operationalize an adaptive platform trial for glioblastoma patients, a deadly disease state for which there are few existing treatment options.
PRESENTED BY
Richard Hamermesh, D.B.A., Co-Faculty Chair, Harvard Business School Kraft Precision Medicine Accelerator; and
Ariel D. Stern, Ph.D., Assistant Professor, Technology and Operations Management Unit, Harvard Business School
INTRODUCTION | Steven D. Averbuch, M.D., Vice President, Head of Precision Medicine, Bristol-Myers Squibb
AWARDEE | Ellen V. Sigal, Ph.D., Chairperson, Founder, Friends of Cancer Research
The original architects of the personalized medicine paradigm envisioned an era in which clinicians could predict, prevent and treat disease based on an improved understanding of how human biology interacts with external environments. During this session, a panel of experts will examine our progress on each of these fronts during a wide-ranging conversation about personalized medicine’s past, present and future.
MODERATOR | Cynthia Casson Morton, Ph.D., William Lambert Richardson Professor of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School
Birgit Funke, Ph.D., F.A.C.M.G., Vice President, Clinical Affairs, Veritas Genetics; Associate Professor of Pathology (Part-Time), Harvard Medical School
Luba Greenwood, J.D., Strategic Business Development and Corporate Ventures, Verily (an Alphabet company)
Keith Stewart, M.B., CH.B., Carlson and Nelson Endowed Director, Center for Individualized Medicine, Mayo Clinic
Advocates for personalized medicine have contended that genomic sequencing can deliver clinical and economic value to patients and the health system by allowing providers to more efficiently diagnose disease and develop treatment plans. Following increased use of genomic sequencing in clinical settings, many stakeholders, including payers, have begun to examine that value proposition more closely. During this session, a pharmaceutical industry representative, a payer, and a health economist will discuss the status and future of the emerging evidence regarding the clinical and economic utility of genomic sequencing, including studies recently commissioned by the Personalized Medicine Coalition.
MODERATOR | Daryl Pritchard, Ph.D., Senior Vice President, Science Policy, Personalized Medicine Coalition
Aris Baras, M.D., Vice President, Head, Regeneron Genetics Center, Regeneron Pharmaceuticals
Kristine Bordenave, M.D., F.A.C.P., Corporate Medical Director, Humana
Scott Ramsey, M.D., Ph.D., Full Member, Fred Hutchinson Cancer Research Center; Director, Hutchinson Institute for Cancer Outcomes Research
INTRODUCTION | Daryl Pritchard, Ph.D., Senior Vice President, Science Policy, Personalized Medicine Coalition
PRESENTER | Shreeram Aradhye, M.D., Head of Global Medical Affairs, Chief Medical Officer, Pharmaceuticals, Novartis; Board Member, PhRMA Foundation
Light refreshments provided.
Sustaining the pace of innovation in personalized medicine will require continued investment in new initiatives, but the financial outlook for the field remains unclear. In that context, this panel of investors will examine whether personalized medicine is at an impasse, an inflection point or somewhere in between.
MODERATOR | William A. Sahlman, Ph.D., Baker Foundation Professor, Harvard Business School
Gregory Dorn, M.D., President, Hearst Health
Cary Pfeffer, M.D., Partner, Third Rock Ventures
Michael Pellini, M.D., Managing Partner, Section 32; Board Member, Personalized Medicine Coalition
Salveen Richter, C.F.A., Vice President, Research Division, Goldman Sachs
SPEAKER | Edward Abrahams, Ph.D., President, Personalized Medicine Coalition